Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Invested Capital (2022 - 2026)

Zentalis Pharmaceuticals has reported Return on Invested Capital over the past 5 years, most recently at 0.01% for Q1 2026.

  • For Q1 2026, Return on Invested Capital changed 0.0% year-over-year to 0.01%; the TTM value through Mar 2026 reached 0.01%, changed 0.0%, while the annual FY2025 figure was 0.01%, 0.0% changed from the prior year.
  • Return on Invested Capital for Q1 2026 was 0.01% at Zentalis Pharmaceuticals, down from 0.01% in the prior quarter.
  • Over five years, Return on Invested Capital peaked at 0.01% in Q2 2024 and troughed at 0.01% in Q1 2026.
  • A 5-year average of 0.01% and a median of 0.01% in 2023 define the central range for Return on Invested Capital.
  • On a YoY basis, Return on Invested Capital climbed as much as 0bps in 2023 and fell as far as 0bps in 2023.
  • Year by year, Return on Invested Capital stood at 0.01% in 2022, then fell by -24bps to 0.01% in 2023, then grew by 15bps to 0.01% in 2024, then fell by -18bps to 0.01% in 2025, then decreased by -12bps to 0.01% in 2026.
  • Business Quant data shows Return on Invested Capital for ZNTL at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.